

# Track 1

## ***PRESCRIBER EDUCATION AND GUIDELINES***

***Track 1 Progress Update – Dave Wuest, Deputy Secretary***

***Panel Presentation: Adoption of Regulations – Status Update***

# Overview of Efforts and Team Members

	<b>Boards, Agencies, and Organizations</b>
<b>Occupational Licensing Boards</b>	Nevada State Board of Medical Examiners Nevada State Board of Osteopathic Medicine Nevada State Board of Nursing Nevada State Board of Pharmacy Nevada State Board of Dental Examiners
<b>Trade Associations and Organizations</b>	Nevada State Medical Association (NSMA) Nevada Dental Association (NDA) Nevada Hospital Association (NHA)
<b>University of Nevada School of Medicine</b>	Project ECHO
<b>Nevada Division of Public and Behavioral Health (DPBH)</b>	
<b>Office of the Governor</b>	

# Overview of Milestones Completed

## Information and Resources Developed

- White paper written to describe the bill in plain language
- “Toolkit” created that includes templates for consent, prescription labels, etc.
- Questions solicited and responses to frequently asked questions posted FAQs

## Information and Education Presented and Distributed to Prescribers

- Prescriber education on AB 474 provided across state including northern, southern, and rural Nevada, and in diverse venues including hospitals, universities, and other sites
- Guidance and meetings provided to address specialized concerns (e.g. Hospice, cancer groups, and others)

## Systems in Place to Support Implementation

- Prescriber education on alternative pain management offered through Project ECHO
- Occupational licensing boards engaged in implementation of AB 474
- Prescriber education on AB 474 posted to web for remote and ongoing access ***Prescribe 365 Nevada (DPBH)***  
<http://prescribe365.nv.gov/>

# Challenges and Issues to Address



# Priorities for Next Quarter

1. Post-Implementation, Boards to identify needs for new or revised regulations

2. New data in Prescription Drug Monitoring Program (PDMP) analyzed and made accessible for utilization by providers

3. Work together and across sectors to ensure prescribers and public in general understand AB 474